Highlights•B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is currently treated by
risk-adapted intensive chemotherapy•Genome-wide genomic analyses have uncovered the …

Traditionally, genetic abnormalities detected by conventional karyotyping, fluorescence in
situ hybridization, and polymerase chain reaction divided childhood B-cell precursor acute …

Most B cell precursor acute lymphoblastic leukemia (BCP ALL) can be classified into known
major genetic subtypes, while a substantial proportion of BCP ALL remains poorly …

Childhood acute lymphoblastic leukemia (ALL) is comprised of multiple subtypes defined by
recurring chromosomal alterations that are important events in leukemogenesis and are …

RAS pathway mutations have been linked to relapse and chemotherapy resistance in
pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However …

B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by genetic
alterations with high heterogeneity. Precise subtypes with distinct genomic and/or gene …

Recent genetic studies using high-throughput sequencing have disclosed genetic
alterations in B-cell precursor acute lymphoblastic leukemia (B-ALL). However, their effects …

Background: Cytogenetic and molecular features of diseases, such as B-cell precursor acute
lymphoblastic leukemia (BCP-ALL), are increasingly used for diagnostic, prognostic, and …

Current risk assessments for treatment of children with B-cell precursor acute lymphoblastic
leukemia (BCP-ALL) are based on several clinical and biological criteria, including genomic …

B-lymphoblastic leukemia/lymphoma, also known as B-acute lymphoblastic leukemia, is
derived from B-cell progenitors. B-acute lymphoblastic leukemia occurs predominantly in …